Background {#S1}
==========

Despite an increase in diagnostic testing capacity for SARS-CoV-2, in many countries, including the United States, testing is still inadequate to slow the COVID-19 pandemic. Many people still do not have access to SARS-CoV-2 tests, and some that do still experience long delays in receiving results due to imbalance between supply and demand at large testing centers. The demand for testing will only increase with the reopening of many schools, colleges, and workplaces. Ideally, specialized population surveillance-oriented testing would (***1***) require minimal diversion of resources from clinical diagnostic testing, (***2***) be affordable and scalable, and (***3***) allow for rapid and reliable identification of virus presence for asymptomatic or subclinical infections. Thus, simplifying the sample collection and testing workflow is critical.

Collecting saliva for SARS-CoV-2 detection is one of the simple solutions needed to massively expand testing. We and others have shown that saliva is a sensitive source for SARS-CoV-2 detection^[@R1]-[@R3]^. Perhaps of equal importance, saliva collection is non-invasive, can be reliably done at home without trained health professions, and does not rely on a sometimes limited supply of swabs. However, the only saliva-based mass testing strategies currently approved by the U.S. Food and Drug Administration (FDA) require specialized collection tubes containing stabilization and/or inactivation buffers that are costly with unreliable availability. Moreover, as saliva continues to gain popularity as a potential specimen to aid testing demands, unlike traditional swab-based methods, standardized collection methods have not been defined. Additionally, when true saliva is not collected (*e.g.* contains sputum), which can happen with COVID-19 inpatients when saliva is difficult to produce, the sample type can be difficult to pipette. Combined with untested concerns regarding SARS-CoV-2 RNA stability in saliva, supplements to reduce degradation and improve sample processing have become common. Prior work from saliva samples, however, has indicated that some buffers optimized for host nucleic acid stabilization may actually inhibit viral RNA detection,^[@R4]-[@R6]^ particularly in extraction-free PCR workflows.^[@R7]^ Thus, if true saliva - which is relatively easy to pipette - is being tested, the utility of collecting saliva in expensive tubes containing purported stabilization buffers comes into question.

To explore the viability of broadly deploying affordable saliva-based surveillance approaches^[@R8]^, we characterized SARS-CoV-2 RNA stability and virus infectivity from saliva samples stored in widely available, sterile, nuclease-free laboratory plastic (polypropylene) tubes. We found stable detection of SARS-CoV-2 RNA in saliva samples at a range of temperatures and for prolonged periods, supporting the potential for inexpensive and simple saliva collection.

Results {#S2}
=======

Saliva collected from COVID-19 inpatients and healthcare workers using sterile collection tubes^[@R2]^ was used to evaluate the temporal stability of SARS-CoV-2 RNA at different holding temperatures (−80°C, 4°C, \~19°C, 30°C) without using nucleic acid preservatives. Importantly, we found that SARS-CoV-2 RNA from saliva was consistently detected at similar levels regardless of the holding time and temperatures tested. Following RNA extraction^[@R9]^ and RT-qPCR^[@R10]^ testing for SARS-CoV-2 on the day of saliva collection^[@R2]^, the remaining sample volumes (n=20) were aliquoted and stored at −80°C, room temperature (recorded as \~19°C) and 30°C. Whether tested on day of collection or after storage at −80°C freeze/thaw, room temperature (5 days), and 30°C (3 days), RT-qPCR cycle threshold (Ct) values for N1 were not significantly different ([Figure 1A](#F1){ref-type="fig"}). Following the freeze/thaw cycle or storage at room temperature, we observed Ct decreases of 1.058 (95% CI: −2.289, 0.141) and 0.960 (95% CI: −2.219, 0.266), respectively; however the strength of this effect was low. A similar effect was seen following incubation at 30°C with an increase of Ct 0.973 (95% CI: −0.252, 2.197). Moreover, SARS-CoV-2 RNA remained relatively stable in saliva samples left for up to 25 days at room temperature (\~19°C; Ct increase of 0.027, 95% CI: −0.019, 0.071) ([Figure 1B](#F1){ref-type="fig"}). This finding is in line with a recent study also reporting on the stability of SARS-CoV-2 RNA in saliva at room temperature for up to 7 days^[@R6]^. Regardless of the starting Ct value (and therefore viral load), this prolonged stability of SARS-CoV-2 RNA was also observed when samples were stored for longer periods at −80°C (max. 92 days), 4°C (max. 21 days), and 30°C (max. 16 days) ([Supplemental Figure 1](#SD1){ref-type="supplementary-material"}).

Interestingly, while SARS-CoV-2 RNA from saliva remained stable over time, we observed a decrease in human *RNAse P* (RP) at higher temperatures (room temperature, Ct +1.837, 95% CI: 0.468, 3.188; 30°C, Ct +3.526, 95% CI: 1.750, 5.349; [Supplemental Figure 2](#SD1){ref-type="supplementary-material"}), with the change in concentration greater than that observed for SARS-CoV-2 RNA ([Supplemental Figure 3](#SD1){ref-type="supplementary-material"}). Thus, our data indicates that while human RNA from saliva degrades without stabilization buffers, SARS-CoV-2 RNA remains protected even at warm temperatures suited for nuclease activity.

As saliva has been shown to have antiviral properties^[@R11],[@R12]^, we explored the infectiousness of SARS-CoV-2 present in saliva samples. We inoculated Vero-E6 cells with saliva samples of higher virus RNA titers ([Supplemental Figure 4](#SD1){ref-type="supplementary-material"}), as others have shown that SARS-CoV-2 isolation is uncommon at low virus RNA titers^[@R13]-[@R16]^. By 72 hours post-inoculation, five of the 43 (11.6%) saliva samples cultured exhibited a reduction in Ct values when tested by RT-qPCR (−4.41, −4.3, −3.86, −3.49 and −2.66, [Figure 2](#F2){ref-type="fig"}). While these findings suggest an increase in the number of SARS-CoV-2 RNA copies by 72 hours, this may not definitively demonstrate active viral replication. For instance, Ct reductions could also likely result from sampling artifacts or assay variations (disparities in inoculation, RNA extraction, and RT-qPCR). To determine whether this amplification resulted from active viral replication, we performed plaque assays with cellular lysate from 72 hours post-inoculation. Interestingly, no plaque forming units (PFU) could be visualized after 48 hours post-infection. This may suggest that the increase in SARS-CoV-2 genome copies identified by RT-qPCR may not have resulted from viral replication, that infectious virus falls below the limit of detection (100 PFU/mL), or possibly that components of saliva inhibit active viral particle production and release. A similar result was observed when attempting to plaque virus from the colon^[@R17]^, despite studies showing that SARS-CoV-2 infected gut enterocytes^[@R18]^.

Discussion {#S3}
==========

Inexpensive saliva-based SARS-CoV-2 testing methods are urgently needed to help reach the capacity needed to safely reopen schools and workplaces. We demonstrate the stability of SARS-CoV-2 RNA detection for prolonged periods in a variety of settings, which indicates that saliva can be simply collected without the need of expensive additives. With commercial tubes being promoted as specialized for the collection of saliva and stabilization of SARS-CoV-2 RNA costing over \$7 per tube ([Table 1](#T1){ref-type="table"}), these costs can be prohibitive to mass testing efforts. Moreover, previous studies have demonstrated the ease in which saliva can be collected in simple, wide-mouth containers^[@R2],[@R9],[@R19]^ and that buffers marketed for RNA stabilization may be detrimental to SARS-CoV-2 detection^[@R6]^. Without the need for RNA stabilization and with limited evidence of viral replication in saliva samples, simple, sterile, nuclease-free plastic containers are affordable alternatives to making testing accessible throughout the country. SARS-CoV-2 stability at both room temperature and 30°C permits more affordable collection and transport strategies without a need for expensive cooling strategies. Without the requirement for cold chain handling, this also facilitates the implementation of saliva testing in regions or countries with limited resources. Thus, collection of saliva in simple, sterile, nuclease-free tubes, negating the high costs associated with specialized collection devices, is one of the keys to meet mass testing demands.

Methods {#S4}
=======

RNA extraction and SARS-CoV-2 detection {#S5}
---------------------------------------

RNA was extracted from saliva samples^[@R9]^ collected from COVID-19 inpatients and healthcare workers at the Yale-New Haven Hospital (Yale Human Research Protection Program Institutional Review Boards FWA00002571, Protocol ID. 2000027690)^[@R2]^. RNA templates were tested by RT-qPCR for SARS-CoV-2 RNA (N1)^[@R10]^ on day of collection (\~12 hours post collection) and at various time points after the storage of the remaining, unsupplemented samples at temperatures of −80°C, −20°C, +4°C, 19°C, or 30°C.

Cell culture {#S6}
------------

Vero-E6 cells (ATCC) were cultured in Dulbecco's Modified Eagle Medium (Gibco) supplemented with 10% heat-inactivated fetal bovine serum (VWR), 1% Penicillin/Streptomycin (Gibco), 100 μg/mL gentamicin (Gibco), and 0.5 μg/mL amphotericin B (Fisher Scientific). All cells were incubated at 37°C and 5% CO~2~. All cell culture experiments were performed in a biosafety level 3 laboratory at Yale University and approved by the Yale University Biosafety Committee.

Saliva inoculation and serial passaging in Vero-E6 cells {#S7}
--------------------------------------------------------

Saliva samples were diluted 1:1 in 1X Dulbecco's PBS (Gibco). Diluted saliva samples were incubated for one hour at 37°C with 2.5x10^5^ Vero-E6 cells in a 24-well plate (Corning). Unbound virus was aspirated and the media were replaced. Infected Vero-E6 cells were frozen at −80°C at 1 and 72 hours post-inoculation. Prior to RNA extraction^[@R9]^ and RT-qPCR detection of SARS-CoV-2 RNA^[@R10]^ the Vero-E6 cells from 1 and 72 hours post-inoculation were thawed at room temperature and further lysed by diluting 1:3 in MagMax Binding Solution (ThermoFisher). RNA was extracted from the two timepoints and tested in RT-qPCR for SARS-CoV-2 N1. We interpreted a Ct reduction \>2 as a difference which could potentially be explained by viral replication during the two timepoints.

Plaque assay {#S8}
------------

Vero-E6 cells were seeded at 4x10^5^ cells/well in 12-well plates. The following day, media were removed and replaced with 100ul of 10-fold serial dilutions of thawed 72 hour post-inoculation saliva samples. Plates were incubated at 37°C for 1 hour with gentle rocking every 10 mins. Unbound inocula was aspirated from each well and overlay media (DMEM, 2% FBS, 0.6% Avicel RC-581 (DuPont)) was added to each well. At 48 hours post-infection, plates were fixed with 5-10% formaldehyde for 30 min then stained with crystal violet solution (0.5% crystal violet in 20% ethanol) for 30 mins. Crystal violet solution was then aspirated, and plates were washed in tap water to visualize plaques.

Statistical analyses {#S9}
--------------------

We fit a linear regression to the experimental stability data to model the change in Ct values of positive samples following stability conditions using the equation below. Let dct be the change in Ct value from fresh testing following each storage condition and let condition be the categorical storage condition (e.g. freeze/thaw, room temperature, 30°C, etc).

dct

∼

condition

Robust confidence intervals were simulated from this model using the mvrnorm, in the R package "MASS", and quantile functions. This regression was also used to model the effect of prolonged storage in stability conditions on RP.

For extended timepoint analyses of N1 we used a linear mixed effects model to predict the change in Ct values of positive samples under each stability condition for greater durations of time using the equation below. Let timepoint be the number of days under stability conditions and let sample be the patient number.
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)

Confidence intervals were computed for this model using confint.merMod, in the R package "lme4".

Further statistical analyses were conducted in GraphPad Prism 8.0.0 as described in the text and figure legends.
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![Stability of SARS-CoV-2 RNA detection in saliva.\
SARS-CoV-2 RNA detection in (A) saliva (n=20) on day of sample collection (fresh) or after storage at −80°C, 30°C for 3 days or room temperature (RT, recorded as \~19°C) for 5 days. The detection of RNA remained stable regardless of starting Ct value (Pearson's r = −0.085, *p* = 0.518). At room temperature (B), detection remained stable for up to 25 days. Ct values from the same sample in different conditions are connected by a dotted line. The black dashed line represents Ct 38 which we applied as the cut-off to determine sample positivity. Samples that remained not detected (ND) after 45 cycles are depicted as Ct 42.](nihpp-2020.08.03.20165233-f0001){#F1}

![Viral load of saliva samples tested for infectious SARS-CoV-2.\
Starting viral load (calculated from RT-qPCR detection of N1) of saliva samples incubated with Vero-E6 cells for 72 hours. Orange diamonds depict samples in which a reduction in Ct value of \>2 at 72 hours post-inoculation was observed as compared to 1 hour post-inoculation. Plaque assays with the cellular lysate from 72 hours post-inoculation however, resulted in no plaque forming units (PFU) after 48 hours post-infection.](nihpp-2020.08.03.20165233-f0002){#F2}

###### 

Possible saliva collection devices: type, approach and list price (USD) per sample.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tube type                                                                          Collection                     Buffer type                                                                                                                           Cost per\                                  Brand/s             Vendor/s
                                                                                                                                                                                                                                                          sample^[\#](#TFN1){ref-type="table-fn"}^                       
  ---------------------------------------------------------------------------------- ------------------------------ ------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------ ------------------- -------------------------------------------------
  Oragene®•Dx collection device (OGD-510)[\*](#TFN2){ref-type="table-fn"}            Funnel                         Ethanol \<24% Tris 1-5% (host DNA stabilization)                                                                                      \$28.00                                    Genotek             DNAgenotek

  Saliva collection kit                                                              Funnel                         Unknown                                                                                                                               \$22.47                                    IBI Scientific      VWR

  sDNA-1000 small tubes[\*](#TFN2){ref-type="table-fn"}                              Widemouth tube                 Ethanol 10-25% Tris 1-5% Thiocyanic Acid:Guanidine (1:1) 25-50% pH 7.9-8.3                                                            \$17.99                                    Spectrum            RhUSA, Spectrum

  Saliva RNA Collection and Preservation Device                                      Widemouth tube                 Unknown liquid, colorless, odorless                                                                                                   \$18                                       Norgen (Biotek)     Nbs Scientific

  Liquid biopsy/spit devices                                                         Complicated unit (various)     Unknown                                                                                                                               \$9-12 each                                Oasis Diagnostics   4saliva

  OMNIgene®·ORAL saliva collection device (OM-505)[\*](#TFN2){ref-type="table-fn"}   Funnel                         Sodium dodecyl sulphate 1-5% Glycine,N,N\'-trans-1,2-cyclohexanediylbis\[N-(carboxymethyl)-, hydrate 1-5% Lithium chloride 0.5-1.5%   \$9.50                                     Genotek             DNAgenotek

  GeneFix saliva DNA/RNA collection                                                  Funnel                         Unknown liquid, colorless                                                                                                             \$9                                        Isohelix            Medicalexpo Bocascientific Brooks Life Sciences

  DNA/RNA Shield™ saliva collection kit[\*](#TFN2){ref-type="table-fn"}              Widemouth tube                 Unknown liquid, colorless, pH 5.0-7                                                                                                   \$7.25                                     Zymo Research       VWR

  Saliva collection system                                                           Small beaker                   Unknown                                                                                                                               Unavailable                                Greiner Bio         Greiner Bio

  Pedia Sal infant saliva collection                                                 Soother + passive collector    None                                                                                                                                  Unavailable                                Oasis Diagnostics   4saliva

  Oral swab                                                                          Swab                           None                                                                                                                                  \$1.76                                     Saliva Bio          Salimetrics

  Saliva collection aid + cryovial                                                   Straw + 2 mL collection vial   None                                                                                                                                  \$1.36/straw, \$0.76/vial                  Salimetrics         Salimetrics

  Urine collection cups                                                              Wide-mouth cup                 None                                                                                                                                  \$0.47                                     ThermoFisher        ThermoFisher

  Sterile tube, large volume                                                         Wide-mouth tube                None                                                                                                                                  \$0.46 (25mL) \$0.38 (5mL)                 Eppendorf           USA Scientific

  Sterile tube, small volume                                                         Narrow-mouth tube              None                                                                                                                                  \$0.16 (2mL)                               ThermoFisher        ThermoFisher
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

list prices, shown in USD

currently FDA EUA approved for saliva-based diagnostics
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